Cambium Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 1.45 Cr
as on 24-10-2024
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 11.55 Cr
as on 24-10-2024
- Revenue 40.08%
(FY 2023)
- Profit 853.61%
(FY 2023)
- Ebitda 49.42%
(FY 2023)
- Net Worth 100.47%
(FY 2023)
- Total Assets 87.55%
(FY 2023)
About Cambium Biotech
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.45 Cr.
The company has closed loans amounting to ₹11.55 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Jha Neelkamal, Ambrish Kashyap, and Naresh Kedia serve as directors at the Company.
- CIN/LLPIN
U15400MH2011PTC216776
- Company No.
216776
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Apr 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Cambium Biotech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jha Neelkamal  | Director | 27-Apr-2011 | Current |
| Ambrish Kashyap | Director | 28-May-2011 | Current |
| Naresh Kedia | Additional Director | 30-Jul-2022 | Current |
Financial Performance of Cambium Biotech.
Cambium Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 40.08% increase. The company also saw a substantial improvement in profitability, with a 853.61% increase in profit. The company's net worth Soared by an impressive increase of 100.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cambium Biotech?
In 2023, Cambium Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Uco Bank Creation Date: 05 Jan 2012 | ₹11.55 Cr | Satisfied |
How Many Employees Work at Cambium Biotech?
Unlock and access historical data on people associated with Cambium Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cambium Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cambium Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
